Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695561 | 0.83 | FAAH (0.45) | ALDH1A1TSHRFAAHZDHHC20ZDHHC2 | |
| SCHEMBL11762886 | 0.76 | CA12 (0.41) | ALDH1A1MGLLCA12CA1CA2 | |
| SCHEMBL9423866 | 0.73 | FAAH (0.42) | ALDH1A1TSHRFAAHCA12CA1 | |
| SCHEMBL29428 | 0.71 | CA12 (0.46) | ALDH1A1TSHRFAAHMGLLCA12 | |
| SCHEMBL7746903 | 0.70 | FAAH (0.40) | ALDH1A1TSHRFAAHCA12CA1 | |
| SCHEMBL10906487 | 0.69 | FAAH (0.53) | ALDH1A1TSHRFAAHMGLLCA12 | |
| SCHEMBL1545275 | 0.69 | TSHR (0.38) | ALDH1A1TSHRFAAHMGLLCA12 | |
| SCHEMBL7976647 | 0.69 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTGAAHPGD | |
| SCHEMBL2364576 | 0.68 | FAAH (0.39) | ALDH1A1TSHRFAAHZDHHC20ZDHHC2 | |
| SCHEMBL7688794 | 0.68 | FAAH (0.40) | ALDH1A1TSHRFAAHZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975158-B9 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-1975158-B1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| EP-1975158-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | HDAC1, HDAC11, HDAC5 | ALDH1A1 469/4885TSHR 3970/4885FAAH 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.